Worth taking a look - Qualigen Worth a medium investment for the mid term.
A bit later then usual (okt - dec)!
It's now low cap season and they are catching up the big ones!
And maybe this was a hint?
QUALIGEN THERAPEUTICS INC FILES FOR PROSPECTUS BY THE SELLING STOCKHOLDER OF UP TO 5.2 MILLION SHARES OF COMMON STOCK- SEC FILING
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−80.66 USD
−12.81 M USD
0.00 USD
496.27 K
About Qualigen Therapeutics, Inc.
Sector
CEO
Kevin A. Richardson
Headquarters
Carlsbad
Website
Founded
2004
FIGI
BBG008D03RS4
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Carlsbad, CA.
Target 6-8Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug can
$QLGNQualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-
QLGNQualigen Therapeutics Inc (NASDAQ:QLGN) I think this stock will post a sharp rally from current levels following the earnings report on Friday after-hours. The company announced a revenue increase of 30% from last year and cash equivalents approximately $21.9 Million, providing sufficient runway to
QLGN; A Good Idea, but can they make it happen?DISCLAIMER
This is in no way, shape or form, fluid and function, an analytical, qualitative or intelligent compte rendu. I am obviously not rich, so obviously I haven't made it with my own thinking, so definitely don't put faith in me. But maybe read and learn some things about a company that may o
QLGN: INVERTED HEAD AND SHOULDER, BOUNCE PLAYQLGN
The price is retesting the neckline of the inverted head and shoulder . It is potentially a very good support for a long entry.
I'm playing the bounce with the red line as target (swing trade).
I'll close the trade if we break below the neckline.
Trade safe.
QLGN ready for take offHello tradingview community. This is my first post here so hopefully will get better as time goes on. I feel thus is getting primed to take off soon. Maybe as soon as Tomorrow February 1 2021. I see a good setup going and candle formation. I dont know how to explain it yet but I can "see" it happen
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of QLGN is 4.77 USD — it has increased by 5.30% in the past 24 hours. Watch Qualigen Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Qualigen Therapeutics, Inc. stocks are traded under the ticker QLGN.
QLGN stock has fallen by −4.60% compared to the previous week, the month change is a −43.55% fall, over the last year Qualigen Therapeutics, Inc. has showed a −86.56% decrease.
QLGN reached its all-time high on Jun 24, 2015 with the price of 13,749.75 USD, and its all-time low was 0.08 USD and was reached on Oct 24, 2024. View more price dynamics on QLGN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
QLGN stock is 12.53% volatile and has beta coefficient of 2.91. Track Qualigen Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Qualigen Therapeutics, Inc. there?
Today Qualigen Therapeutics, Inc. has the market capitalization of 2.62 M, it has decreased by −4.81% over the last week.
Yes, you can track Qualigen Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Qualigen Therapeutics, Inc. is going to release the next earnings report on Nov 12, 2024. Keep track of upcoming events with our Earnings Calendar.
QLGN net income for the last quarter is −1.48 M USD, while the quarter before that showed −2.03 M USD of net income which accounts for 27.36% change. Track more Qualigen Therapeutics, Inc. financial stats to get the full picture.
No, QLGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 4.00 employees. See our rating of the largest employees — is Qualigen Therapeutics, Inc. on this list?
Like other stocks, QLGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Qualigen Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Qualigen Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Qualigen Therapeutics, Inc. stock shows the sell signal. See more of Qualigen Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.